[ad_1]
Boston, July 25, 2022 /PRNewswire/ — HotSpot Therapeutics, Inc., a biotechnology company that discovers and develops small molecule allosteric therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has been appointed. Paul Thibodeau, Ph.D., as Chief Business Officer. Dr. Thibodeau brings nearly 20 years of business development experience in the biopharmaceutical industry.
“We are thrilled to welcome Paul to Hotspot as Chief Business Officer,” he said. Jonathan MontaguCo-founder and CEO of HotSpot Therapeutics. “Paul’s significant industry experience and proven track record in biopharmaceutical business development will be critical as we advance our oncology and autoimmune programs and expand our pipeline through partnerships powered by the Smart Allostery™ platform.”
Dr. Thibodeau joins from Novartis Hotspot, where he held multiple business development positions, leading recent M&A transactions across all Novartis therapeutic areas, and was responsible for execution and execution of acquisitions and divestitures. In the year Prior to joining Novartis in 2016, he served as Senior Director of Global Business Development at Teva Cephalon, where he coordinated all licensing and acquisition agreements on a specialty pipeline. Previously, he held several business development positions at Sanofi Genzyme with increasing responsibilities in the oncology, transplant and multiple sclerosis franchises. Dr. Thibodeau was a postdoctoral research fellow at the Institut National Scientifique et de la Recherche Médecine (INSERM). Paris, France. Dr. Thibodeau received his Ph.D. in Cell Biology and Radiobiology from the University of Sherbrooke in Quebec, Canadaand a bachelor’s degree in biology and biochemistry from the University of Moncton in New Brunswick, Canada. He completed his MBA degree MIT Sloan School of Management.
“I am thrilled to be joining Hotspot’s leadership and innovation team at such an important time for the company,” said Dr. Thibodeau. “I look forward to working with the team as they seek to bring new treatments to patients with critical unmet needs.”
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. He is targeting naturally occurring pockets on certain proteins that he calls “natural hotspots” that are critical to regulating cellular protein function. Largely unexploited in industry, these pockets offer the systematic design of highly potent and selective small molecules that have great potential for drug discovery and exhibit novel pharmacology. It believes the company’s proprietary Smart Allostery™ platform uses computational approaches and AI-driven data mining to identify natural hotspots using large and highly diverse data sets, combined with a customized pharmacology toolkit and Spock chemistry to enable rapid delivery of advanced hotspot targeting. Small molecules. Hotspot has established a diverse pipeline of allosteric small molecules for the treatment of cancer and immunological diseases. To learn more, visit www.hotspotthera.com.
SOURCE HotSpot Therapeutics
[ad_2]
Source link
